Lexicon Pharmaceuticals (LXRX) Competitors

$2.00 +0.32 (+19.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.89 -0.11 (-5.50%)

As of 06:09 PM Eastern

LXRX vs. BCRX, CLDX, INVA, NVAX, and ZBIO

Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

BioCryst Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.02	-$50.34M	-$0.14	N/A
BioCryst Pharmaceuticals	$885.72M	2.47	$263.86M	-$1.78	N/A

In the previous week, BioCryst Pharmaceuticals had 12 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 23 mentions for BioCryst Pharmaceuticals and 11 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.47 beat BioCryst Pharmaceuticals' score of 0.12 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexicon Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

BioCryst Pharmaceuticals has a net margin of -51.71% compared to Lexicon Pharmaceuticals' net margin of -101.08%. Lexicon Pharmaceuticals' return on equity of -41.94% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-101.08%	-41.94%	-22.03%
BioCryst Pharmaceuticals	-51.71%	-91.42%	59.88%

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals currently has a consensus price target of $4.15, suggesting a potential upside of 107.50%. BioCryst Pharmaceuticals has a consensus price target of $20.70, suggesting a potential upside of 140.14%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

BioCryst Pharmaceuticals beats Lexicon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Lexicon Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lexicon Pharmaceuticals presently has a consensus target price of $4.15, indicating a potential upside of 107.50%. Celldex Therapeutics has a consensus target price of $46.64, indicating a potential upside of 37.29%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Lexicon Pharmaceuticals and 7 mentions for Celldex Therapeutics. Lexicon Pharmaceuticals' average media sentiment score of 0.47 beat Celldex Therapeutics' score of -0.26 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celldex Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexicon Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.02	-$50.34M	-$0.14	N/A
Celldex Therapeutics	$1.55M	1,725.81	-$258.76M	-$4.26	N/A

Celldex Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -101.08%. Celldex Therapeutics' return on equity of -41.67% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-101.08%	-41.94%	-22.03%
Celldex Therapeutics	N/A	-41.67%	-38.86%

Summary

Lexicon Pharmaceuticals beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Innoviva?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Lexicon Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.

Innoviva has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.02	-$50.34M	-$0.14	N/A
Innoviva	$420.69M	4.03	$271.17M	$6.01	3.81

Innoviva has a net margin of 119.89% compared to Lexicon Pharmaceuticals' net margin of -101.08%. Innoviva's return on equity of 36.58% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-101.08%	-41.94%	-22.03%
Innoviva	119.89%	36.58%	24.10%

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals presently has a consensus target price of $4.15, suggesting a potential upside of 107.50%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 58.15%. Given Lexicon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Lexicon Pharmaceuticals had 3 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for Lexicon Pharmaceuticals and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.36 beat Lexicon Pharmaceuticals' score of 0.47 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats Lexicon Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Novavax?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Lexicon Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.

Novavax has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	17.02	-$50.34M	-$0.14	N/A
Novavax	$1.12B	1.48	$440.30M	$2.41	4.20

Novavax has a net margin of -14.73% compared to Lexicon Pharmaceuticals' net margin of -101.08%. Novavax's return on equity of -17.64% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-101.08%	-41.94%	-22.03%
Novavax	-14.73%	-17.64%	1.18%

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals presently has a consensus target price of $4.15, suggesting a potential upside of 107.50%. Novavax has a consensus target price of $12.13, suggesting a potential upside of 19.93%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

In the previous week, Novavax had 22 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 33 mentions for Novavax and 11 mentions for Lexicon Pharmaceuticals. Novavax's average media sentiment score of 0.65 beat Lexicon Pharmaceuticals' score of 0.47 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	12 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novavax beats Lexicon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Lexicon Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	112.68	-$377.74M	-$7.81	N/A
Lexicon Pharmaceuticals	$49.80M	17.02	-$50.34M	-$0.14	N/A

Zenas BioPharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -101.08%. Lexicon Pharmaceuticals' return on equity of -41.94% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-85.64%	-61.86%
Lexicon Pharmaceuticals	-101.08%	-41.94%	-22.03%

Zenas BioPharma currently has a consensus target price of $44.14, suggesting a potential upside of 124.76%. Lexicon Pharmaceuticals has a consensus target price of $4.15, suggesting a potential upside of 107.50%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Zenas BioPharma has a beta of -0.61, suggesting that its stock price is 161% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 8 more articles in the media than Zenas BioPharma. MarketBeat recorded 11 mentions for Lexicon Pharmaceuticals and 3 mentions for Zenas BioPharma. Lexicon Pharmaceuticals' average media sentiment score of 0.47 beat Zenas BioPharma's score of 0.42 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lexicon Pharmaceuticals beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$847.36M	$3.37B	$6.18B	$12.29B
Dividend Yield	N/A	2.22%	2.78%	5.24%
P/E Ratio	-14.28	35.07	28.73	27.27
Price / Sales	17.02	187.69	507.29	64.11
Price / Cash	N/A	125.28	43.30	53.97
Price / Book	6.67	7.35	10.00	6.83
Net Income	-$50.34M	$23.67M	$3.54B	$332.87M
7 Day Performance	N/A	N/A	N/A	0.09%
1 Month Performance	19.76%	5.27%	4.66%	7.36%
1 Year Performance	193.26%	76.22%	40.41%	41.09%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	2.3612 of 5 stars	$2.00 +19.0%	$4.15 +107.5%	+148.5%	$847.36M	$49.80M	N/A	140	News Coverage Earnings Report High Trading Volume
BCRX BioCryst Pharmaceuticals	3.6785 of 5 stars	$9.20 +0.1%	$19.64 +113.4%	-11.7%	$2.34B	$874.84M	7.67	530	News Coverage Earnings Report Analyst Forecast
CLDX Celldex Therapeutics	2.3404 of 5 stars	$32.77 +1.4%	$46.36 +41.5%	+76.2%	$2.15B	$1.54M	N/A	150	News Coverage Positive News Earnings Report Upcoming Earnings Analyst Forecast
INVA Innoviva	3.85 of 5 stars	$22.99 -0.5%	$34.80 +51.4%	+21.7%	$1.71B	$411.33M	7.54	100	News Coverage Positive News Earnings Report Analyst Forecast
NVAX Novavax	1.734 of 5 stars	$8.03 -0.1%	$11.88 +47.9%	+55.1%	$1.32B	$1.12B	3.33	1,990	Trending News Earnings Report Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. BCRX, CLDX, INVA, NVAX, and ZBIO

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. BCRX, CLDX, INVA, NVAX, and ZBIO

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Which has better earnings and valuation, LXRX or BCRX?

Does the media favor LXRX or BCRX?

Which has more risk & volatility, LXRX or BCRX?

Is LXRX or BCRX more profitable?

Do insiders & institutionals have more ownership in LXRX or BCRX?

Do analysts rate LXRX or BCRX?

Summary

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Which has more risk and volatility, LXRX or CLDX?

Do institutionals & insiders have more ownership in LXRX or CLDX?

Do analysts recommend LXRX or CLDX?

Does the media prefer LXRX or CLDX?

Which has stronger valuation & earnings, LXRX or CLDX?

Is LXRX or CLDX more profitable?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Which has more volatility & risk, LXRX or INVA?

Which has higher earnings & valuation, LXRX or INVA?

Is LXRX or INVA more profitable?

Do insiders and institutionals have more ownership in LXRX or INVA?

Do analysts recommend LXRX or INVA?

Does the media favor LXRX or INVA?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Which has more volatility & risk, LXRX or NVAX?

Which has higher earnings & valuation, LXRX or NVAX?

Is LXRX or NVAX more profitable?

Do insiders and institutionals have more ownership in LXRX or NVAX?

Do analysts recommend LXRX or NVAX?

Does the media favor LXRX or NVAX?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Which has better earnings & valuation, ZBIO or LXRX?

Is ZBIO or LXRX more profitable?

Do analysts rate ZBIO or LXRX?

Which has more risk and volatility, ZBIO or LXRX?

Do institutionals and insiders have more ownership in ZBIO or LXRX?

Does the media refer more to ZBIO or LXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools